We are live on
!
Find out more
RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$9.44B
1-Year Est. Return
68.42%
This Fund
S&P 500
This Quarter
Est. Return
-14.58%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$862M
(-31%)
Cap. Flow
-$479M
Cap. Flow
% of AUM
-25.16%
Top 10 Holdings %
Top 10 Hldgs %
43.35%
Holding
99
New
27
Increased
22
Reduced
5
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WillScot Mobile Mini Holdings
WSC
|
+$46.7M |
| 2 |
BRSL
Brightstar Lottery PLC
BRSL
|
+$27.4M |
| 3 |
Apollo Global Management
APO
|
+$24.9M |
| 4 |
COOP
Mr. Cooper
COOP
|
+$23.1M |
| 5 |
Insmed
INSM
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$44.7M |
| 2 |
New Fortress Energy
NFE
|
+$36.8M |
| 3 |
Chegg
CHGG
|
+$33.4M |
| 4 |
AAR Corp
AIR
|
+$21.6M |
| 5 |
FerroAtlántica
GSM
|
+$14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.91% |
| 2 | Industrials | 18.53% |
| 3 | Energy | 12.47% |
| 4 | Financials | 10.45% |
| 5 | Consumer Discretionary | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Advantage Solutions
ADV
$393M
| $7.18M | 0.38% |
75,583
| – | – |
|
52
Regenxbio
RGNX
$730M
| $7.1M | 0.37% |
+287,467
| New | +$7.18M |
|
|
SWIR
53
DELISTED
Sierra Wireless
SWIR
| $6.92M | 0.36% |
295,683
| – | – |
|
54
MediaAlpha
MAX
$778M
| $6.25M | 0.33% |
634,579
| – | – |
|
55
Ovid Therapeutics
OVID
$491M
| $6.2M | 0.33% |
+2,882,706
| New | +$6.97M |
|
56
Krystal Biotech
KRYS
$9.84B
| $6.08M | 0.32% |
+92,609
| New | +$5.76M |
|
|
AVEO
57
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $6.06M | 0.32% |
+923,885
| New | +$4.47M |
|
58
Invivyd
IVVD
$208M
| $5.94M | 0.31% |
+1,812,347
| New | +$5.68M |
|
59
BioXcel Therapeutics
BTAI
$31.8M
| $5.17M | 0.27% |
24,478
+7,695
| +46% | +$1.62M |
|
60
Kiniksa Pharmaceuticals
KNSA
$6.06B
| $5.07M | 0.27% |
+523,528
| New | +$4.88M |
|
61
Trevi Therapeutics
TRVI
$2.55B
| $5M | 0.26% |
+1,778,420
| New | +$4.37M |
|
62
Arcutis Biotherapeutics
ARQT
$3.27B
| $4.82M | 0.25% |
+226,346
| New | +$4.64M |
|
63
AtaiBeckley Inc
ATAI
$2.68B
| $4.8M | 0.25% |
+1,319,137
| New | +$5.39M |
|
64
Sutro Biopharma
STRO
$321M
| $4.69M | 0.25% |
+90,000
| New | +$5.03M |
|
65
CytomX Therapeutics
CTMX
$760M
| $4.4M | 0.23% |
2,406,449
| – | – |
|
66
Precision BioSciences
DTIL
$207M
| $4.25M | 0.22% |
+88,571
| New | +$5.2M |
|
67
ARS Pharmaceuticals
SPRY
$590M
| $4.18M | 0.22% |
+986,453
| New | +$3.44M |
|
68
Cullinan Oncology
CGEM
$1.26B
| $3.81M | 0.2% |
+297,347
| New | +$3.37M |
|
|
TSVT
69
DELISTED
2seventy bio
TSVT
| $3.5M | 0.18% |
+265,000
| New | +$3.61M |
|
|
XOMA
70
DELISTED
Xoma
XOMA
| $3.33M | 0.17% |
+149,446
| New | +$3.07M |
|
71
Cellebrite
CLBT
$3.85B
| $3.21M | 0.17% |
629,020
| – | – |
|
|
CMPS
72
Compass Pathways
CMPS
$1.93B
| $3.07M | 0.16% |
+283,694
| New | +$2.86M |
|
73
Tarsus Pharmaceuticals
TARS
$3.06B
| $2.96M | 0.16% |
+202,648
| New | +$3.04M |
|
|
VINC
74
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $2.78M | 0.15% |
105,350
| – | – |
|
75
ANI Pharmaceuticals
ANIP
$1.71B
| $2.45M | 0.13% |
+82,444
| New | +$2.38M |
|
Similar funds
RCM
SIM
NPT
AC
PVI
WPL
IAA
LAMI
Rubric Capital Management (New York)'s Q2 2022 Portfolio in Review
As of Q2 2022, Rubric Capital Management (New York) held 99 positions worth $1.9B, down 31% from $2.77B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Rubric Capital Management (New York) withdrew a net $479M in Q2 2022, closing 11 positions and reducing 5 holdings. Its most notable exit was Antares Pharma, Inc., an estimated $44.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 14% a quarter earlier, followed by Industrials and Energy.
Against the trend, Rubric Capital Management (New York) opened a new position in WillScot Mobile Mini Holdings worth $42.8M.
- Rubric Capital Management (New York)'s largest Q2 2022 buy was WillScot Mobile Mini Holdings: 1,320,713 shares worth $42.8M.
- Rubric Capital Management (New York) added most to Apollo Global Management in Q2 2022, an estimated $24.9M increase.
- Rubric Capital Management (New York)'s biggest Q2 2022 reduction was New Fortress Energy, cutting an estimated $36.8M.
- Rubric Capital Management (New York) fully exited Antares Pharma, Inc. in Q2 2022, selling an estimated $44.7M.
- Rubric Capital Management (New York)'s ten largest holdings make up 43% of its $1.9B portfolio in Q2 2022.
- Rubric Capital Management (New York) opened 27 new positions and closed 11 in Q2 2022.
- Rubric Capital Management (New York)'s portfolio value fell 31% quarter-over-quarter to $1.9B.
Based on Rubric Capital Management (New York)'s 13F filing for Q2 2022, filed 12 Aug 2022.